PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide–copper complex first identified in human plasma in 1973 by Dr Loren Pickart. Unlike synthetic peptide analogues, GHK-Cu is an endogenous molecule — measurable in healthy human serum — whose circulating concentrations are known to decline significantly with age. It has since become one of the most studied tripeptides in the fields of dermatological science, wound biology, and antioxidant cellular research. For licensed research laboratories in Ireland, Peptides Lab Ireland supplies GHK-Cu as a lyophilised research-grade compound for exclusive use in approved in-vitro experimental settings.
GHK-Cu has the molecular formula C₁₄H₂₃CuN₆O₄ and a molecular weight of 403.9 Da. It is formed from the tripeptide glycyl-L-histidyl-L-lysine (GHK) chelated to a single copper(II) ion via the imidazole nitrogen of histidine and the terminal amine of glycine. This copper chelation is not merely structural — it is functionally central to GHK-Cu’s biological activity profile, as the copper ion participates in redox signalling and enzyme co-factor pathways studied in the research literature.
The compound is water-soluble, pale blue in solution due to its copper content, and exhibits high stability at physiological pH ranges. In lyophilised form it presents as a pale blue to turquoise powder, distinguishing it visually from most other peptide research compounds.
GHK-Cu has accumulated a substantial body of preclinical literature spanning several decades. Key mechanistic areas under study include:
Early in vitro studies demonstrated that GHK-Cu stimulates fibroblast proliferation and upregulates collagen synthesis — specifically type I and type III collagen — in human dermal fibroblast cultures. Subsequent work identified modulation of matrix metalloproteinase (MMP) activity, particularly MMP-2 and MMP-9, alongside tissue inhibitor of metalloproteinases (TIMP) expression. This bidirectional modulation — promoting collagen synthesis while regulating collagen degradation — has made GHK-Cu a persistent subject of interest in wound healing and tissue remodelling research programmes.
GHK-Cu has been studied in the context of reactive oxygen species (ROS) modulation. Research indicates it upregulates superoxide dismutase (SOD) and catalase activity — two principal enzymatic antioxidant defence pathways. Additionally, studies in cell line models have reported reductions in NF-κB-mediated inflammatory cytokine expression (IL-6, TNF-α) following GHK-Cu exposure, suggesting potential relevance to oxidative stress and chronic low-grade inflammation models.
A landmark 2012 analysis by Pickart et al. applied bioinformatic approaches to archived gene expression databases, identifying GHK as a modulator of 31 of the 54 genes altered in aggressive metastatic colon cancer cell lines — resetting expression profiles toward a more differentiated phenotype. Subsequent transcriptomic research identified associations with over 4,000 gene expression changes when GHK concentrations were modelled in silico, including pathways related to DNA repair, stem cell renewal, and neurological maintenance. These findings have generated significant academic interest, though they require continued experimental validation.
In preclinical wound healing models, GHK-Cu has been studied in the context of angiogenesis — the formation of new blood vessels — which is a rate-limiting step in tissue repair. Research has demonstrated upregulation of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in GHK-Cu-exposed cell cultures. Animal wound model studies have reported accelerated wound closure and improved collagen organisation at the healing site compared to vehicle controls.
Emerging research has explored GHK-Cu in the context of nerve regeneration, with in vitro studies demonstrating stimulation of neurite outgrowth and nerve growth factor (NGF) synthesis in neuronal cell lines. While the evidence base here is less mature than in wound healing or collagen research, it represents an active area of scientific investigation.
Human plasma GHK concentrations average approximately 200 ng/mL in young adults but fall to levels below 80 ng/mL in older individuals. This age-associated decline has been proposed as one factor contributing to reduced wound healing capacity and skin structural integrity in older populations. Research programmes investigating the relationship between endogenous GHK-Cu decline, oxidative stress accumulation, and tissue maintenance represent an active area of geroscience investigation, particularly relevant to Irish academic institutions with programmes in age-related biology.
GHK-Cu is studied across dermatological science, wound biology, antioxidant cellular models, angiogenesis, and transcriptomic/gene expression research. It is one of the most characterised naturally occurring peptide complexes in the research literature, with studies dating back to the 1970s.
GHK-Cu is an endogenous molecule — it naturally occurs in human plasma, saliva, and urine. Research-grade GHK-Cu supplied by Peptides Lab Ireland is synthetically produced to achieve the purity and consistency required for laboratory work, and is structurally identical to the endogenous compound.
GHK-Cu is not classified as a controlled substance under Irish law or the Misuse of Drugs Acts 1977–2016. It may be purchased and held by qualified researchers for licensed in-vitro research purposes. It is not a licensed medicine and is not for human use.
The characteristic pale blue colour of GHK-Cu in solution and lyophilised form derives from the copper(II) ion in its chelated structure. This is a useful visual indicator confirming the presence of the copper complex and can be used as a basic quality check during reconstitution.
Store lyophilised GHK-Cu at −20°C in a dry, dark environment. Once reconstituted, store solutions at 4°C for up to 14 days or at −80°C for longer-term storage. Avoid repeated freeze-thaw cycles to preserve peptide integrity.
Legal Disclaimer: All compounds supplied by Peptides Lab Ireland are intended exclusively for in-vitro laboratory and scientific research purposes by licensed, qualified researchers. They are not medicines, not licensed therapeutic products, and not for human or veterinary administration. Peptides Lab Ireland does not provide medical advice, treatment recommendations, or dosage guidance for any human or clinical application. Use of any research compound must comply with all applicable Irish and EU legislation, including HPRA regulations and institutional ethics requirements.
Receive News
